Receptor TrK
Os inibidores dos receptores Trk têm como alvo as quinases receptoras da tropomiosina (Trk), uma família de tirosina quinases receptoras que desempenham um papel significativo no desenvolvimento e função do sistema nervoso. Os receptores Trk estão envolvidos na sinalização de neurotrofinas, essencial para a sobrevivência, diferenciação e crescimento dos neurônios. A desregulação da sinalização Trk está associada a distúrbios neurológicos e certos tipos de câncer. Na CymitQuimica, oferecemos inibidores dos receptores Trk para apoiar sua pesquisa em neurobiologia, oncologia e doenças neurodegenerativas.
Foram encontrados 56 produtos de "Receptor TrK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CE-245677
CAS:CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.Fórmula:C24H22Cl2N6O3Pureza:98.99% - 99.23%Cor e Forma:SolidPeso molecular:513.38Ref: TM-T14921
1mg58,00€2mg82,00€5mg113,00€1mL*10mM (DMSO)129,00€10mg177,00€25mg296,00€50mg409,00€100mg605,00€Amitriptyline hydrochloride
CAS:Amitriptyline hydrochloride (Annoyltin) is the hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptiveFórmula:C20H24ClNPureza:97% - 99.94%Cor e Forma:Crystals White To Off-White PowderPeso molecular:313.86N-Acetyl-5-hydroxytryptamine
CAS:N-Acetyl-5-hydroxytryptamine, or Normelatonin, is melatonin's precursor, made from serotonin, and activates TrkB receptor.
Fórmula:C12H14N2O2Pureza:98.31% - 99.91%Cor e Forma:SolidPeso molecular:218.25Protein kinase inhibitor 5 sulfate hydrate
Protein kinase inhibitor 5 sulfate hydrate, a potent TRK-A inhibitor, exhibits an IC50 of 1.8 nM and impairs cell viability [1].Fórmula:C29H35F2N7O6SPureza:98%Cor e Forma:SolidPeso molecular:647.69GNF-8625 monopyridin-N-piperazine hydrochloride
CAS:GNF-8625 monopyridin-N-piperazine hydrochloride is a protomyosin receptor kinase (TRK) inhibitor.Fórmula:C25H27ClFN7Pureza:98.97%Cor e Forma:SolidPeso molecular:479.98Anti-TrkB/NTRK2 Antibody
Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.Cor e Forma:Odour LiquidAdimanebart
CAS:Amdokitug is a human-derived IgG1λ monoclonal antibody that acts as an inhibitor of MUSK.Cor e Forma:LiquidAnti-NGF/bNGF Antibody (AS2886401-00)
Anti-NGF/bNGF Antibody (AS2886401-00) is a human monoclonal antibody (mAb) targeting NGF/bNGF. It inhibits intracellular calcium (Ca2+) influx and provides sustained analgesic effects during movement in an osteoarthritis (OA) rat model. This antibody is applicable for research in osteoarthritis.Cor e Forma:Odour LiquidTrkA-IN-6
TrkA-IN-6 (compound R48) is a hydrazone-based, selective inhibitor of the tropomyosin receptor kinase A (TrkA). It exhibits greater cytotoxicity towards U87 GBM cells compared to Temozolomide, with an IC50 of 68.99 μM.Fórmula:C16H13N3O5Peso molecular:327.08552CRB-0089
CRB-0089 is a human monoclonal antibody targeting NGF/bNGF. It is used in the study of analgesia.Cor e Forma:Odour LiquidPF-06737007
CAS:PF-06737007 is an effective inhibitor of pan-Trk in cell-based assays (IC50s: 7.7 nM, 15 nM, and 3.9 nM for TrkA, TrkB, and TrkC, respectively).Fórmula:C25H28F4N2O6Pureza:98%Cor e Forma:SolidPeso molecular:528.49Entrectinib
CAS:Entrectinib (RXDX-101) is an orally Trk, ROS1, and ALK inhibitor. Entrectinib exhibits antitumor activity. Cost-effective and quality-assured.Fórmula:C31H34F2N6O2Pureza:98.03% - 99.61%Cor e Forma:SolidPeso molecular:560.64Ref: TM-T3678
2mg42,00€5mg59,00€1mL*10mM (DMSO)69,00€10mg88,00€25mg111,00€50mg168,00€100mg283,00€500mg692,00€Selitrectinib
CAS:Selitrectinib (LOXO-195) is a potent and selective inhibitor of the receptor tyrosine kinases(TRK).Cost-effective and quality-assured.Fórmula:C20H21FN6OPureza:99.55% - ≥95%Cor e Forma:SolidPeso molecular:380.42LM22A-4
CAS:LM22A-4: BDNF mimetic, TrkB agonist, IC50=47 nM (fluorescence anisotropy).
Fórmula:C15H21N3O6Pureza:99.56%Cor e Forma:SolidPeso molecular:339.34Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Cor e Forma:SolidPeso molecular:510.46Larotrectinib
CAS:Larotrectinib (LOXO-101) is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).Fórmula:C21H22F2N6O2Pureza:99.15% - >99.99%Cor e Forma:SolidPeso molecular:428.44Ref: TM-T5995
1mg37,00€5mg74,00€1mL*10mM (DMSO)81,00€10mg90,00€25mg157,00€50mg236,00€100mg356,00€500mg820,00€CH7057288
CAS:CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB and TRKC, respectively.Fórmula:C32H31N3O5SPureza:99.92%Cor e Forma:SolidPeso molecular:569.67Belizatinib
CAS:Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.Fórmula:C33H44FN5O3Pureza:99.33% - 99.44%Cor e Forma:SolidPeso molecular:577.73Ref: TM-T4257
1mg40,00€2mg54,00€5mg93,00€1mL*10mM (DMSO)105,00€10mg133,00€25mg259,00€50mg358,00€100mg500,00€LOXO-195
CAS:(6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.Fórmula:C20H21FN6OPureza:99.54%Cor e Forma:SolidPeso molecular:380.42GNF-5837
CAS:GNF-5837 is a specific, and orally bioavailable pan-TRK inhibitor for TrkA/TrkB (IC50: 8/12 nM).Fórmula:C28H21F4N5O2Pureza:97.26% - 98.08%Cor e Forma:SolidPeso molecular:535.49Ref: TM-T6097
5mg48,00€1mL*10mM (DMSO)52,00€10mg80,00€25mg117,00€50mg178,00€100mg295,00€200mg384,00€500mg622,00€Cyclotraxin B acetate(1203586-72-4 free base)
Cyclotraxin B acetate is an antagonist of TrkB receptors; inhibits BDNF-induced TrkB activity (IC50 = 0.30 nM).Fórmula:C50H77N13O19S3Pureza:99.42%Cor e Forma:SolidPeso molecular:1260.42DS-1205
CAS:DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Fórmula:C41H42FN5O7Pureza:99.75%Cor e Forma:SolidPeso molecular:735.8GW 441756
CAS:GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.Fórmula:C17H13N3OPureza:97.73% - 99.8%Cor e Forma:SolidPeso molecular:275.3Tyrphostin AG 879
CAS:Tyrphostin AG 879 (AG 879) effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.Fórmula:C18H24N2OSPureza:99.05%Cor e Forma:SolidPeso molecular:316.46ONO-7475
CAS:ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinaseFórmula:C32H26N4O6Pureza:98.74%Cor e Forma:SolidPeso molecular:562.57ANA-12
CAS:ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice.
Fórmula:C22H21N3O3SPureza:99.28% - 99.87%Cor e Forma:SolidPeso molecular:407.497,8-Dihydroxyflavone
CAS:7,8-Dihydroxyflavone (7,8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.Fórmula:C15H10O4Pureza:98.48% - 99.81%Cor e Forma:SolidPeso molecular:254.24Repotrectinib
CAS:Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
Fórmula:C18H18FN5O2Pureza:99.92% - >99.99%Cor e Forma:SolidPeso molecular:355.37Larotrectinib sulfate
CAS:Larotrectinib sulfate (LOXO-101 sulfate) is an oral active and specific ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).Fórmula:C21H22F2N6O2·H2O4SPureza:98.62% - 99.76%Cor e Forma:SolidPeso molecular:526.51Ref: TM-T6880
2mg37,00€5mg54,00€1mL*10mM (DMSO)63,00€10mg88,00€25mg124,00€50mg155,00€100mg259,00€500mg623,00€LM22B-10
CAS:LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.Fórmula:C27H33ClN2O4Pureza:98.18%Cor e Forma:SolidPeso molecular:485.01Sitravatinib
CAS:Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, andFórmula:C33H29F2N5O4SPureza:98.9% - 99.85%Cor e Forma:SolidPeso molecular:629.68Ref: TM-T4349
5mg49,00€1mL*10mM (DMSO)69,00€10mg74,00€25mg130,00€50mg200,00€100mg319,00€200mg507,00€500mg800,00€Frunevetmab
CAS:Frunevetmab (NV-02) is a feline-adapted monoclonal antibody targeting NGF (nerve growth factor), with a Kd value of 20 pM. Feline osteoarthritis (OA).Pureza:95% - 95.3% (SDS-PAGE); 98.7% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:147.99 kDaTanezumab
CAS:Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF，pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.Pureza:95%Cor e Forma:LiquidPeso molecular:145.43 kDaFulranumab
CAS:Fulranumab (AMG-403) is a humanised monoclonal antibody targeting NGF, analgesic effects, and can be used for the study of chronic pain.Pureza:95%Cor e Forma:LiquidPeso molecular:145.37 kDaFasinumab
CAS:Fasinumab (anti-NGF mAb) is in Phase III trials for acute sciatica & knee OA. It significantly improves pain & function vs. placebo.Pureza:95%Cor e Forma:LiquidPeso molecular:144.89 kDaTrkA-IN-1
CAS:TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) (IC50: 99 nM in a cell-based assay) with analgesic activity.Fórmula:C25H20N4OPureza:98%Cor e Forma:SolidPeso molecular:392.45Protein kinase inhibitor 5
CAS:Protein kinase inhibitor 5 is a potent inhibitor of TRK-A, demonstrating an IC50 of 1.8 nM, and effectively suppresses cell viability [1].Fórmula:C29H31F2N7OPureza:98%Cor e Forma:SolidPeso molecular:531.6Tavilermide
CAS:Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.Fórmula:C24H32N6O11Pureza:98.98%Cor e Forma:SolidPeso molecular:580.54ENT-C225
CAS:ENT-C225 is a potent TrkB neurotrophin receptor (TrkBR) activator with neuroprotective activity for the study of Alzheimer's disease and Parkinson's disease.Fórmula:C26H40N4O5Pureza:99.36% - 99.36%Cor e Forma:SolidPeso molecular:488.62PF-06733804
CAS:PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.Fórmula:C20H19F5N4O4Pureza:98%Cor e Forma:SolidPeso molecular:474.38Paltimatrectinib
CAS:Paltimatrectinib (PBI-200) is a tyrosine kinase inhibitor with anticancer activity, and is used in the study of bladder, breast, and colorectal cancers.Fórmula:C20H15F5N6Pureza:99.96%Cor e Forma:SolidPeso molecular:434.37TRK-IN-24
CAS:TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,Fórmula:C39H45N7O3Pureza:98%Cor e Forma:SolidPeso molecular:659.82Type II TRK inhibitor 1
CAS:Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.Fórmula:C35H33F3N8O3Pureza:98%Cor e Forma:SolidPeso molecular:670.68AZ-23
CAS:AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.Fórmula:C17H19ClFN7OPureza:99.4%Cor e Forma:SolidPeso molecular:391.83TrkA-IN-9
CAS:TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.Fórmula:C31H32N4O4Cor e Forma:SolidPeso molecular:524.61TrkC-IN-1
CAS:TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.Fórmula:C28H20BrN5O2Cor e Forma:SolidPeso molecular:538.395BNN-20
CAS:BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.Fórmula:C20H30O2Cor e Forma:SolidPeso molecular:302.45TRK-IN-28
CAS:TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].Fórmula:C27H25F2N7Cor e Forma:SolidPeso molecular:485.53TRK-IN-26
CAS:TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].Fórmula:C30H22F2N6O4Cor e Forma:SolidPeso molecular:568.53TrkA-IN-7
CAS:TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.Fórmula:C16H13N3O3Cor e Forma:SolidPeso molecular:295.293
